Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

0.23USD
3:59pm EST
Change (% chg)

$0.02 (+11.14%)
Prev Close
$0.21
Open
$0.23
Day's High
$0.23
Day's Low
$0.22
Volume
388,309
Avg. Vol
271,114
52-wk High
$1.78
52-wk Low
$0.19

CLSN.OQ

Chart for CLSN.OQ

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $6.95
Shares Outstanding(Mil.): 33.07
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -0.90 -- --
ROI: -60.80 -3.35 12.96
ROE: -124.36 5.80 14.11

BRIEF-Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy

* Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy at the ASCO-SITC clinical immuno-oncology symposium

8:44am EST

BRIEF-Celsion Corp announces $5.0 mln public offering

* Celsion Corp - offering was priced at $0.23 per share of common stock

Feb 15 2017

BRIEF-Celsion provides update on immunotherapy study in ovarian cancer patients

* Celsion announces continuing positive data from the ovation study - an immunotherapy study of newly diagnosed stage iii and iv ovarian cancer patients

Nov 10 2016

BRIEF-Celsion Corp reports Q3 loss per share $0.23

* Celsion corporation reports third quarter 2016 financial results and provides business update

Nov 10 2016

BRIEF-Celsion files for resale of up to 8.8 mln shares of co's common stock

* Files for resale of up to 8.8 million shares of co's common stock by selling stockholders - SEC filing Source text for Eikon: [http://bit.ly/2dWdFbl] Further company coverage:

Oct 31 2016

BRIEF-Celsion corp gets positive DSMB review of Phase Ib ovation study

* Says future studies of GEN-1 will include a phase I/II study combining GEN-1 with avastin and doxil

Sep 15 2016

More From Around the Web

Competitors

Earnings vs. Estimates